Interface Migration projects shouldn’t be disruptive
January 7, 2015
If you’re selecting a new interface engine, you know you’re in for some pain as the team migrates interfaces from the legacy engine to the
If you’re selecting a new interface engine, you know you’re in for some pain as the team migrates interfaces from the legacy engine to the
Have a wonderful holiday season and wishing you the best for 2014!
New interface selection: a big decision Is your team selecting a new interface engine? If so, you’re in good company. With DataGate/eGate and eBiz at
Last week, we talked about how you can do more with less by applying a lifecycle approach to your interface and interoperability work. By managing
If you’re responsible for interfacing within a hospital system, a consulting organization, or an HIE, you know one thing: you need to do more with
You already know that HL7® messages are a rich source of actionable insight about your clinical and financial operations. To get to that insight, start
HL7® message samples should be system-specific When you build interfaces, you need HL7® message samples and test messages for your validation workflow. It’s tempting to
Interoperability barriers and HIE business models In a previous post, we talked about the interoperability barriers facing HIEs (healthcare information exchanges). What are they? Primarily
The purpose of HL7 interface validation In the interface lifecycle, validation is critical. HL7 interface validation is about checking the interface you’ve developed: making sure
Caristix release 3.2 is a broad release of additional features through the range of Caristix products from Workgroup through the individual HL7 modules, Cloak, Conformance,
NORTH AMERICA: +1 (877)-872-0027
WORLD: 1-418-872-4000
EMAIL: info@caristix.com
ASIA-PACIFIC
DENIS CANTIN
T: +61418441388
denis.cantin@caristix.com
NORTH AMERICA & EUROPE
JEAN-LUC MORIN
T: 418 872-4000
jeanluc.morin@caristix.com
HL7® / FHIR® are a registered trademarks of Health Level Seven International. The use of this trademark does not constitute an endorsement by HL7.